腫瘤學市場規模、佔有率、成長分析、按癌症診斷/治療、按癌症類型、按最終用途、按地區 - 行業預測，2024-2031 年

2022年全球腫瘤市場規模約2018億美元，高於2023年的2,244億美元，預測期內（2024-2031年）複合年成長率為11.2%，到2031年將達到4718億美元。

癌症是世界上第三大致命疾病，僅次於心血管疾病、寄生蟲疾病和感染疾病。因此，由於迫切需要有效的治療解決方案，腫瘤市場正在經歷顯著成長。化學預防，即使用合成或天然存在的化學物質來抑制癌變，正變得越來越重要。目前的癌症治療方法包括手術、放射線治療和藥物介入。手術仍然是早期癌症的主要治療方法，對於局部腫瘤，放射線治療通常與手術一起進行。此外，藥物治療，特別是使用各種細胞毒藥物的化療，在治療策略中扮演重要角色。針對促進癌細胞增殖和轉移的特定基因變化的標靶治療正在成為有前途的治療方法。由於酒精和菸草消費量的增加，癌症盛行率不斷上升，凸顯了創新解決方案的緊迫性。因此，產業公司正在大力投資開發旨在解決多種惡性的新型治療候選藥物。隨著相關人員繼續尋求治療方法的進步，這種對研究和開發的關注預計將在預測期內改善治療結果並推動市場成長。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 監管分析
• 案例研究分析
• 技術分析
• 價格分析
• 臨床試驗

腫瘤市場：按癌症診斷和治療分類

• 市場概況
• 癌症診斷
  • 切片檢查
  • 影像
  • 免疫組織化學
  • 腫瘤生物標記檢測
  • 原位雜合技術
  • 液態生物檢體
• 癌症治療
  • 標靶治療
  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 其他

腫瘤市場：市場：依適應症分類

• 市場概況
• 肺癌
• 大腸直腸癌
• 乳癌
• 肝癌
• 膀胱癌
• 頭頸癌
• 攝護腺癌
• 其他

腫瘤學市場：依最終用途分類

• 市場概況
• 醫院
• 診斷實驗室
• 影像診斷中心
• 學術界
• 專科診所
• 其他

腫瘤學市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Roche Holding AG
• Novartis International AG
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca plc
• Johnson & Johnson（Janssen Pharmaceuticals）
• Eli Lilly and Company
• Amgen Inc.
• Sanofi SA
• Bayer AG
• Takeda Pharmaceutical Company
• AbbVie Inc.
• Gilead Sciences, Inc.
• Astellas Pharma Inc.
• Celgene Corporation（acquired by Bristol-Myers Squibb）
• Regeneron Pharmaceuticals, Inc.
• GlaxoSmithKline plc（GSK）
• Daiichi Sankyo Company, Limited
• Seagen Inc.

Global Oncology Market size was valued at around USD 201.8 billion in 2022 and is expected to rise from USD 224.4 billion in 2023 to reach a value of USD 471.8 billion by 2031, at a CAGR of 11.2% over the forecast period (2024-2031).

Cancer ranks as the third most lethal disease globally, trailing only behind cardiovascular, parasitic, and infectious diseases. As a result, the market for oncology is experiencing significant growth driven by the urgent need for effective treatment solutions. Chemoprevention, which involves using synthetic or naturally occurring chemicals to inhibit carcinogenesis, is becoming increasingly relevant. Current cancer treatment methodologies encompass surgery, radiation therapy, and pharmacological interventions. Surgery remains the primary treatment choice for early-stage cancer, while radiotherapy is often employed alongside surgical procedures for localized tumors. Additionally, pharmacotherapy, particularly chemotherapy that utilizes a variety of cytotoxic agents, plays a crucial role in management strategies. Targeted therapy, which addresses specific genetic alterations in cancer cells that promote their growth and metastasis, is gaining traction as a promising treatment avenue. The escalating prevalence of cancer due to rising alcohol and tobacco consumption underscores the urgency for innovative solutions. Consequently, industry players are heavily investing in the development of novel therapeutic candidates aimed at addressing the diverse spectrum of malignancies. This focus on research and development is poised to enhance treatment outcomes and propel market growth throughout the forecast period, as stakeholders continue to seek advancements in oncology therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Market Segmental Analysis

Global Oncology Market is segmented by Cancer Diagnostics & Treatment, Cancer Type, End Use, and region. Based on Cancer Diagnostics & Treatment, the market is segmented into Cancer Diagnostics (Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization), Cancer Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy). Based on Cancer Type, the market is segmented into Lung Cancer, Prostate Cancer, Colon & Rectal Cancer, Gastric Cancer, Esophageal Cancer, Liver Cancer, and Breast Cancer. Based on End Use, the market is segmented into Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia, Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Oncology Market

The global oncology market is poised for significant growth, primarily driven by the alarming rise in cancer prevalence worldwide, currently the second leading cause of death after cardiovascular diseases. Factors such as tobacco use, shifting dietary habits, and an increase in life expectancy contribute to this surge, with the World Health Organization projecting new cancer cases to skyrocket from 18.1 million in 2018 to an anticipated 29.4 million by 2040. This escalating burden necessitates effective oncology medications, thereby bolstering market demand. Furthermore, heightened public awareness of cancer risks and treatment options is expected to further stimulate market expansion in the coming years.

Restraints in the Global Oncology Market

The global oncology market faces several significant restraints that hinder its growth trajectory. Adverse drug effects associated with chemotherapy, such as bone marrow suppression, gastrointestinal disorders, neuropathies, and hair loss, not only compromise patient quality of life but also lead to treatment discontinuation, thereby limiting market expansion. Additionally, stringent regulatory frameworks governing drug approvals and high medication costs pose significant barriers for pharmaceutical companies. Furthermore, the impending patent expirations of key oncology drugs introduce competitive pressures, causing a decline in revenue for innovators and stalling investment in new therapies. Collectively, these factors present formidable challenges to the market's progress in the coming years.

Market Trends of the Global Oncology Market

The Global Oncology market is witnessing a robust trend of expansion, driven by an intensified focus on research and development (R&D) for advanced drug therapies, particularly in immunotherapy. As cancer treatment increasingly prioritizes curing the disease, prolonging survival, and enhancing patients' quality of life, market leaders are channeling significant investments into immunotherapy research. The collaboration between companies like FUJIFILM Corporation and the National Cancer Center Japan highlights a growing emphasis on innovative treatments that leverage immune cells to combat tumors. This strategic shift towards effective immunotherapeutic solutions is not only improving patient outcomes but also propelling substantial growth within the oncology sector.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Regulatory Analysis
• Case Study Analysis
• Technology Analysis
• Pricing Analysis
• Clinical Trials

Oncology Market, By Cancer Diagnostics & Treatment

• Market Overview
• Cancer Diagnostics
  • Biopsy
  • Imaging
  • Immunohistochemistry
  • Tumor Biomarkers Test
  • In Situ Hybridization
  • Liquid Biopsy
• Cancer Treatment
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Others

Oncology Market, By Indication

• Market Overview
• Lungs Cancer
• Colorectal Cancer
• Breast Cancer
• Liver Cancer
• Bladder Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

Oncology Market, By End Use

• Market Overview
• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Academia
• Specialty clinics
• Others

Oncology Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (acquired by Bristol-Myers Squibb)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seagen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments